Pembrolizumab + platinum + paclitaxel ± bevacizumab (cervical)
Checked 2026-09-09
Persistent, recurrent or metastatic cervical cancer, PD-L1 CPS 1 or above
One cycle
every 21 daysComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Pembrolizumab Monoclonal antibody (anti-PD-1) | 200 mg | IV | D1 | or 400 mg every 6 weeks |
Paclitaxel Cytotoxic chemotherapy (taxane) | 175 mg/m² | IV | D1 | |
Cisplatin 50 mg/m² or carboplatin AUC 5 Cytotoxic chemotherapy (platinum) | day 1 | IV | D1 | |
Bevacizumab (optional) Monoclonal antibody (anti-VEGF) | 15 mg/kg | IV | D1 |
Cycles
chemotherapy 6; pembrolizumab up to 35
21-day cycle
Emetogenicity
High (>90%)
G-CSF
Not routine
Used in
Trials
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Topotecan
Relapsed SCLC; platinum-resistant ovarian or cervical cancer
every 21 days
Carboplatin + paclitaxel
Ovarian cancer adjuvant or neoadjuvant (6 cycles); advanced endometrial cancer with pembrolizumab or dostarlimab; NSCLC
every 21 days × 6
Weekly cisplatin chemoradiation (with pembrolizumab for high-risk disease)
Locally advanced cervical cancer (FIGO IB2-IVA); pembrolizumab for FIGO 2014 III-IVA or node-positive
weekly × 5-6